Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
Background: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on th...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/7/1396 |
id |
doaj-25422adf71ff424e8d99738bb4d8ff97 |
---|---|
record_format |
Article |
spelling |
doaj-25422adf71ff424e8d99738bb4d8ff972021-03-31T23:02:21ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-01101396139610.3390/jcm10071396Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction FormulaJakub J. Malkiewicz0Maciej Malkiewicz1Joanna Siuda2Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, University Clinical Center Prof. K. Gibiński, 14 Medyków Street, 40-752 Katowice, PolandDepartment of Gastroenterology with Subdivision of Internal Medicine, John Paul II Memorial Beskid Center of Oncology—Municipal Hospital in Bielsko Biala, 21 Stanisława Wyspiańskiego Street, 43-300 Bielsko-Biała, PolandDepartment of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, University Clinical Center Prof. K. Gibiński, 14 Medyków Street, 40-752 Katowice, PolandBackground: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on the QTc length in PD. Methods: 101 patients with PD and a good quality ECG were included in the study. The prolonged QTc was defined as ≥450 ms for men and ≥460 ms for women. Bazett’s (QTcB) and Framingham (QTcF) formulas were utilized to calculate QTc. Data about sex, age, PD duration, disease’s severity, comorbidities and QTc-prolonging drugs were collected. Multiple linear regressions with backward elimination were used to assess factors influencing the QTc. Results: A long QTc was presented in 13 patients (12.9%) for QTcB and 4 patients (4%) for QTcF. Longer QTc in PD patients was associated with older age, male sex and QTc-prolonging drugs regardless of the used formula. The QTcB was also significantly affected by the heart rate (HR). Conclusion: QTc prolongation is common in PD. Age, drugs and male gender are potential risk factors for QTc prolongation in PD.https://www.mdpi.com/2077-0383/10/7/1396Parkinson’s diseaseECGQTc prolongationrisk factorsdrugsage |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jakub J. Malkiewicz Maciej Malkiewicz Joanna Siuda |
spellingShingle |
Jakub J. Malkiewicz Maciej Malkiewicz Joanna Siuda Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula Journal of Clinical Medicine Parkinson’s disease ECG QTc prolongation risk factors drugs age |
author_facet |
Jakub J. Malkiewicz Maciej Malkiewicz Joanna Siuda |
author_sort |
Jakub J. Malkiewicz |
title |
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula |
title_short |
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula |
title_full |
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula |
title_fullStr |
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula |
title_full_unstemmed |
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula |
title_sort |
prevalence of qtc prolongation in patients with parkinson’s disease. assessment of the effects of drugs, clinical risk factors and used correction formula |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-03-01 |
description |
Background: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on the QTc length in PD. Methods: 101 patients with PD and a good quality ECG were included in the study. The prolonged QTc was defined as ≥450 ms for men and ≥460 ms for women. Bazett’s (QTcB) and Framingham (QTcF) formulas were utilized to calculate QTc. Data about sex, age, PD duration, disease’s severity, comorbidities and QTc-prolonging drugs were collected. Multiple linear regressions with backward elimination were used to assess factors influencing the QTc. Results: A long QTc was presented in 13 patients (12.9%) for QTcB and 4 patients (4%) for QTcF. Longer QTc in PD patients was associated with older age, male sex and QTc-prolonging drugs regardless of the used formula. The QTcB was also significantly affected by the heart rate (HR). Conclusion: QTc prolongation is common in PD. Age, drugs and male gender are potential risk factors for QTc prolongation in PD. |
topic |
Parkinson’s disease ECG QTc prolongation risk factors drugs age |
url |
https://www.mdpi.com/2077-0383/10/7/1396 |
work_keys_str_mv |
AT jakubjmalkiewicz prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula AT maciejmalkiewicz prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula AT joannasiuda prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula |
_version_ |
1724177120641417216 |